| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
Comprehensive disease testing
A collaboration with BioPharma Diagnostics includes access to the gastroenterology disease testing capabilities of Mayo Clinic Laboratories, including:
BioPharma Diagnostics partners can access gastroenterology testing for clinical trials and be among the first to use up-and-coming tests currently in development.
The latest
Maria Alice Willrich, Ph.D., explains how Mayo Clinic Laboratories' new assay provides therapeutic drug monitoring of risankizumab, or RISA. Test results help guide care for patients with plaque psoriasis, psoriatic arthritis, and Crohn's disease.
Joshua Bornhorst, Ph.D., associate director of Mayo Clinic's Clinical Immunoassay Lab, explains how humans can develop an allergy to the alpha-gal molecule, and he describes a new allergen antibody test that can be used to detect it. Dr. Bornhorst also reviews other tests that should be used in conjunction with alpha-gal testing to accurately identify the scope and underlying cause of the allergy.
Divyanshu (Div), Dubey, M.B.B.S, gives an overview of the new Autoimmune Gastrointestinal Dysmotility Evaluation available through Mayo Clinic Laboratories. He discusses when this testing should be ordered, how this testing compares to previous testing approaches, and what clinical action can be taken due to the results of this testing.
Matthew Binnicker, Ph.D., Director of the Clinical Virology Laboratory in the Division of Clinical Microbiology at Mayo Clinic, recently spoke with Consultant360 regarding testing for viral gastroenteritis.
Cytomegalovirus, or CMV, is a common cause of disease in the transplant population. In some patients who are diagnosed with CMV and are on antiviral treatment for infections, the virus may develop resistance to the drugs. This “Hot Topic” will provide an overview of a new test developed by Mayo Clinic Laboratories, which uses next-generation sequencing technology to identify mutations in the genome of CMV that may be associated with antiviral resistance.
Joseph Yao, M.D., gives an overview of this new test available through Mayo Clinic Laboratories. He discusses when this testing should be ordered, how this testing improves upon other testing approaches, and what clinical action can be taken due to the results of this testing.
Nikola Baumann, Ph.D., gives an overview of the new NASH-FibroTest available through Mayo Clinic Laboratories. She discusses when this testing should be ordered, how this testing improves upon previous testing approaches, and what clinical action can be taken due to the results of this testing.
This week’s Research Roundup highlights the identification of prognostic phenotypes of esophageal adenocarcinoma in two independent cohorts.
This week’s Research Roundup determines the clinical validity of hereditary colorectal cancer and polyposis susceptibility genes using the clinical genome resource clinical validity framework.
This week’s Research Roundup highlights gastrointestinal and extra-intestinal manifestations of IgG4-related disease.
Many patients may have flare-ups of their disease, or they may stop responding to treatment. In these situations, the clinician may choose to increase the dose administered or recommend more frequent injections. One cause of decreased response to treatment is the appearance of anti-drug antibodies or “immunogenicity.”
This week’s Research Roundup highlights how fasting blood glucose levels provide an estimate of duration and progression of pancreatic cancer before diagnosis.
This week’s Research Roundup highlights gastrointestinal and extra-intestinal manifestations of immunoglobulin G4-related disease.